Research Article Open Access

IMS 1313-nanoparticle Mucosal Vaccine Enhances Immunity Against Avian Influenza and Newcastle Disease Viruses

Authors

Nermeen M. Ismail
Department of Newcastle Disease, Veterinary Serum and Vaccine Research Institute, Abbassia, Cairo, Egypt
|
Ayman H. El-Deeb
Department of Virology, Faculty of Veterinary Medicine, Cairo University, Giza, Egypt
|
Mohamed M. Emara
Department of Virology, Faculty of Veterinary Medicine, Cairo University, Giza, Egypt
|
Hoda I. Tawfik
Department of Newcastle Disease, Veterinary Serum and Vaccine Research Institute, Abbassia, Cairo, Egypt
|
Nabil Abdel Wanis
Department of Newcastle Disease, Veterinary Serum and Vaccine Research Institute, Abbassia, Cairo, Egypt
|
CORRESPONDING AUTHOR
Hussein A. Hussein
Department of Virology, Faculty of Veterinary Medicine, Cairo University, Giza, Egypt
Published on: March 15, 2018
DOI 10.3923/ijps.2018.167.174
PDF

Abstract

Background and Objective: Avian influenza and Newcastle disease viruses are a continuous threat to poultry industry. Vaccines are increasingly used to control these viral infections. This study aimed to develop efficacious vaccines and vaccination strategies against avian influenza and Newcastle disease viruses. Methodology: Two formulations of bivalent vaccines for avian influenza and Newcastle disease viruses were prepared based on the use of IMS1313-nanoparticles (mucosal vaccine) and Montanide ISA71 (parental vaccine) adjuvants. The prepared vaccines were delivered in specific pathogen free (SPF) chickens with different vaccination protocols. Cell mediated and humoral immune response (cytokine expression levels including IFN-γ and IL-6, lymphocyte proliferation, antibodies titers against both H5N1 and NDV) were measured. Challenge trial was carried out to determine the protection percent and shedding pattern of the challenged viruses. Results: Results of the present study revealed a significant increase of IFN-γ and IL-6 genes expression and lymphocytes proliferation in the vaccinated groups compared to the unvaccinated group. Two applications of the mucosal vaccine demonstrated higher hemagglutination inhibition (HI) titers and protection percentage ranged from 40-50% with different levels of virus shedding as measured by qRT-PCR assay. However, when the vaccines were applied in a prime-boost protocol (mucosal-parental, respectively), protection reached 90 and 100% against avian influenza virus (AIV) and Newcastle disease virus (NDV), respectively. No shedding of the NDV-challenge virus was detected whereas, AIV-challenge virus was detected in the samples of the 3rd day post-challenge. Conclusion: Indeed, the use of mucosal-parental vaccines in a prime-boost vaccination protocol demonstrated the potentiality of such approach.

Keywords:

Avian influenza virus, H5N1, IMS1313-nanoparticles, ISA71, NDV genotype VIId, newcastle disease virus, poultry industry

Article Metrics

216 Abstract Views
131 File Views
0 Downloads

License

Copyright (c) 2018 The Author(s)

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.

Article Citation Metrics

Find IMS 1313-nanoparticle Mucosal Vaccine Enhances Immunity Against Avian Influenza and Newcastle Disease Viruses on PlumX

How to Cite

Ismail, N. M., El-Deeb, A. H., Emara, M. M., Tawfik, H. I., Wanis, N. A., & Hussein , H. A. (2018). IMS 1313-nanoparticle Mucosal Vaccine Enhances Immunity Against Avian Influenza and Newcastle Disease Viruses. International Journal of Poultry Science, 17(4), 167–174. https://doi.org/10.3923/ijps.2018.167.174
Crossref
Scopus
Google Scholar
Europe PMC

References

1.
Hikono, H., M. Mase, A. Matsuu, M. Nakayama and T. Saito, 2013. Intraocular vaccination with an inactivated highly pathogenic avian influenza virus induces protective antibody responses in chickens. Vet. Immunol. Immunopathol., 151: 83-89.
2.
OIE., 2015. Avian Influenza. In: Manual of Diagnostic Tests and Vaccines for Terrestrial Animals, OIE (Eds.). Chapter 2.3.4, Office International des Epizooties, Paris, France, pp: 1-23.
3.
Khan, T.A., C.A. Rue, S.F. Rehmani, A. Ahmed, J.L. Wasilenko, P.J. Miller and C.L. Afonso, 2010. Phylogenetic and biological characterization of Newcastle disease virus isolates from Pakistan. J. Clin. Microbiol., 48: 1892-1894.
4.
Kandeil, A., Y. Moatasim, M.R. Gomaa, M.M. Shehata and R. El-Shesheny et al., 2016. Generation of a reassortant avian influenza virus H5N2 vaccine strain capable of protecting chickens against infection with Egyptian H5N1 and H9N2 viruses. Vaccine, 34: 218-224.
5.
Lone, N.A., E. Spackman and D. Kapczynski, 2017. Immunologic evaluation of 10 different adjuvants for use in vaccines for chickens against highly pathogenic avian influenza virus. Vaccine, 35: 3401-3408.
6.
Kim, J.K., G. Kayali, D. Walker, H.L. Forrest and A.H. Ellebedy et al., 2010. Puzzling inefficiency of H5N1 influenza vaccines in Egyptian poultry. Proc. Natl. Acad. Sci. USA., 107: 11044-11049.
7.
Cattoli, G., L. Susta, C. Terregino and C. Brown, 2011. Newcastle disease: A review of field recognition and current methods of laboratory detection. J. Vet. Diagn. Invest., 23: 637-656.
8.
Zhang, L., M. Zhang, J. Li, T. Cao, X. Tian and F. Zhou, 2008. Enhancement of mucosal immune responses by intranasal co-delivery of Newcastle disease vaccine plus CpG oligonucleotide in SPF chickens in vivo. Res. Vet. Sci., 85: 495-502.
9.
Seo, K.Y., S.J. Han, H.R. Cha, S.U. Seo, J.H. Song, S.H. Chung and M.N. Kweon, 2010. Eye mucosa: An efficient vaccine delivery route for inducing protective immunity. J. Immunol., 185: 3610-3619.
10.
Yoshikawa, T., K. Matsuo, K. Matsuo, Y. Suzuki and A. Nomoto et al., 2004. Total viral genome copies and virus-Ig complexes after infection with influenza virus in the nasal secretions of immunized mice. J. Gen. Virol., 85: 2339-2346.
11.
Hasegawa, H., T. Ichinohe, S.I. Tamura and T. Kurata, 2007. Development of a mucosal vaccine for influenza viruses: Preparation for a potential influenza pandemic. Expert Rev. Vaccines, 6: 193-201.
12.
Hong, S.H., Y.H. Byun, C.T. Nguyen, S.Y. Kim and B.L. Seong et al., 2012. Intranasal administration of a flagellin-adjuvanted inactivated influenza vaccine enhances mucosal immune responses to protect mice against lethal infection. Vaccine, 30: 466-474.
13.
Al-Garib, S.O., A.L.J. Gielkens, E. Gruys and G. Kochi, 2003. Review of Newcastle disease virus with particular references to immunity and vaccination. World's Poult. Sci. J., 59: 185-200.
14.
Zhao, K., G. Chen, X.M. Shi, T.T. Gao and W. Li et al., 2012. Preparation and efficacy of a live Newcastle disease virus vaccine encapsulated in chitosan nanoparticles. PLoS ONE, Vol. 7.
15.
Chen, K. and A. Cerutti, 2010. Vaccination strategies to promote mucosal antibody responses. Immunity, 33: 479-491.
16.
Kang, H., H. Wang, Q. Yu and Q. Yang, 2012. Effect of intranasal immunization with inactivated avian influenza virus on local and systemic immune responses in ducks. Poult. Sci., 91: 1074-1080.
17.
Savelkoul, H.F.J., V.A. Ferro, M.M. Strioga and V.E.J.C. Schijns, 2015. Choice and design of adjuvants for parenteral and mucosal vaccines. Vaccines, 3: 148-171.
18.
Pichichero, M.E., 2008. Improving vaccine delivery using novel adjuvant systems. Hum. Vaccines, 4: 262-270.
19.
Park, K.S., J. Lee, S.S. Ahn, Y.H. Byun and B.L. Seong et al., 2009. Mucosal immunity induced by adenovirus-based H5N1 HPAI vaccine confers protection against a lethal H5N2 avian influenza virus challenge. Virology, 395: 182-189.
20.
Jang, S.I., H.S. Lillehoj, S.H Lee, K.W. Lee and E.P. Lillehoj et al., 2011. Montanide™ IMS 1313 N VG PR nanoparticle adjuvant enhances antigen-specific immune responses to profilin following mucosal vaccination against Eimeria acervulina. Vet. Parasitol., 182: 163-170.
21.
Riffault, S., G. Meyer, M. Deplanche, C. Dubuquoy and G. Durand et al., 2010. A new subunit vaccine based on nucleoprotein nanoparticles confers partial clinical and virological protection in calves against bovine respiratory syncytial virus. Vaccine, 28: 3722-3734.
22.
King, D.J., 1991. Evaluation of different methods of inactivation of Newcastle disease virus and avian influenza virus in egg fluids and serum. Avian Dis., 35: 505-514.
23.
Suzuki, K., H. Okada, T. Itoh, T. Tada and M. Mase et al., 2009. Association of increased pathogenicity of Asian H5N1 highly pathogenic avian influenza viruses in chickens with highly efficient viral replication accompanied by early destruction of innate immune responses. J. Virol., 83: 7475-7486.
24.
Londt, B.Z., A. Nunez, J. Banks, H. Nili, L.K. Johnson and D.J. Alexander, 2008. Pathogenesis of highly pathogenic avian influenza A/turkey/Turkey/1/2005 H5N1 in Pekin ducks (Anas platyrhynchos) infected experimentally. Avian Pathol., 37: 619-627.
25.
Wise, M.G., D.L. Suarez, B.S. Seal, J.C. Pedersen and D.A. Senne et al., 2004. Development of a real-time reverse-transcription PCR for detection of Newcastle disease virus RNA in clinical samples. J. Clin. Microbiol., 42: 329-338.
26.
Sasaki, T., N. Isoda, K. Soda, R. Sakamoto and K. Saijo et al., 2009. Evaluation of the potency, optimal antigen level and lasting immunity of inactivated avian influenza vaccine prepared from H5N1 virus. Jpn. J. Vet. Res., 56: 189-198.
27.
Joo, H.M., Y. He, A. Sundararajan, L. Huan and M.Y. Sangster, 2010. Quantitative analysis of influenza virus-specific B cell memory generated by different routes of inactivated virus vaccination. Vaccine, 28: 2186-2194.
28.
Smialek, M., B. Tykalowski, T. Stenzel and A. Koncicki, 2011. Local immunity of the respiratory mucosal system in chickens and turkeys. Polish J. Vet. Sci., 14: 291-297.
29.
Okwor, E.C., D.C. Eze and O.M. Uzuegbu, 2013. Comparative studies on the oral and intraocular routes of administration of Newcastle disease vaccine, La Sota in adult chickens. IOSR J. Agric. Vet. Sci., 3: 48-51.
30.
Van Ginkel, F.W., D.C. Tang, S.L. Gulley and H. Toro, 2009. Induction of mucosal immunity in the avian Harderian gland with a replication-deficient Ad5 vector expressing avian influenza H5 hemagglutinin. Dev. Comp. Immunol., 33: 28-34.
31.
Macpherson, A.J., K.D. McCoy, F.E. Johansen and P. Brandtzaeg, 2008. The immune geography of IgA induction and function. Mucosal Immunol., 1: 11-22.
32.
Lee, D.H., J.K. Park, J.H. Kwon, S.S. Yuk and T.O. Erdene-Ochir et al., 2013. Efficacy of single dose of a bivalent vaccine containing inactivated Newcastle disease virus and reassortant highly pathogenic avian influenza H5N1 virus against lethal HPAI and NDV infection in chickens. PLoS ONE, Vol. 8.
33.
Kryczek, I., S. Wei, L. Vatan, J. Escara-Wilke, W. Szeliga, E.T. Keller and W. Zou, 2007. Cutting edge: Opposite effects of IL-1 and IL-2 on the regulation of IL-17+ T cell pool IL-1 subverts IL-2-mediated suppression. J. Immunol., 179: 1423-1426.
34.
Rauw, F., Y. Gardin, V. Palya, S. Anbari and M. Gonze et al., 2010. The positive adjuvant effect of chitosan on antigen-specific cell-mediated immunity after chickens vaccination with live Newcastle disease vaccine. Vet. Immunol. Immunopathol., 134: 249-258.
35.
Cardenas-Garcia, S., R.P. Dunwoody, V. Marcano, D.G. Diel and R.J. Williams et al., 2016. Effects of chicken interferon Gamma on Newcastle disease virus vaccine immunogenicity. PLoS ONE, Vol. 11.
36.
Julkunen, I., K. Melen, M. Nyqvist, J. Pirhonen, T. Sareneva and S. Matikainen, 2000. Inflammatory responses in influenza A virus infection. Vaccine, 19: S32-S37.
37.
Osterlund, P., V. Veckman, J. Siren, K.M. Klucher, J. Hiscott, S. Matikainen and I. Julkunen, 2005. Gene expression and antiviral activity of alpha/beta interferons and interleukin-29 in virus-infected human myeloid dendritic cells. J. Virol., 79: 9608-9617.
38.
Sharma, J.M., 2003. The Avian Immune System. In: Disease of Poultry, Saif, Y.M., H.J. Barnes, J.R. Glisson, A.M. Fadly, L.R. McDougald and D.E. Swayne (Eds.). 11th Edn., Iowa State Univ. Press, Ames, IA., USA., ISBN-13: 978-0813804231, pp: 5-16.